Anti-Clotting Drug Apixaban Receives NICE Approval

by Kathy Jones on  November 26, 2011 at 5:36 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

British drug regulator National Institute for Health and Clinical Excellence (NICE) has approved the use of the anti-clotting drug manufactured by Pfizer and Bristol-Meyers, apixaban, in preventing blood clots post hip and knee surgery.
 Anti-Clotting Drug Apixaban Receives NICE Approval
Anti-Clotting Drug Apixaban Receives NICE Approval

NICE said that apixaban, which is being marketed under the brand name Eliquis, was a cost effective and clinically effective option in treating blood clots.

The treatment for knee replacement patients will last for 12 days and will cost around £41.16 while it will last for 34 days for hip replacement patients and will cost £116.62.




Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive